Cargando…

Prevalence of Atrial Fibrillation in Patients with High CHADS(2)- and CHA(2)DS(2)VAS(c)-Scores: Anticoagulate or Monitor High-Risk Patients?

BACKGROUND: In patients with known atrial fibrillation (AF) different scores are utilized to estimate the risk of thromboembolic events and guide oral anticoagulation. Diagnosis of AF strongly depends on the duration of electrocardiogram monitoring. The aim of this study was to use established score...

Descripción completa

Detalles Bibliográficos
Autores principales: Tischer, Tina S, Schneider, Ralph, Lauschke, Jörg, Nesselmann, Catharina, Klemm, Anke, Diedrich, Doreen, Kundt, Günther, Bänsch, Dietmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282384/
https://www.ncbi.nlm.nih.gov/pubmed/25621351
http://dx.doi.org/10.1111/pace.12470
_version_ 1782351126986752000
author Tischer, Tina S
Schneider, Ralph
Lauschke, Jörg
Nesselmann, Catharina
Klemm, Anke
Diedrich, Doreen
Kundt, Günther
Bänsch, Dietmar
author_facet Tischer, Tina S
Schneider, Ralph
Lauschke, Jörg
Nesselmann, Catharina
Klemm, Anke
Diedrich, Doreen
Kundt, Günther
Bänsch, Dietmar
author_sort Tischer, Tina S
collection PubMed
description BACKGROUND: In patients with known atrial fibrillation (AF) different scores are utilized to estimate the risk of thromboembolic events and guide oral anticoagulation. Diagnosis of AF strongly depends on the duration of electrocardiogram monitoring. The aim of this study was to use established scores to predict the prevalence of AF. METHODS: The CHADS(2)- (Congestive Heart failure, hypertension, Age >75 years, Diabetes, Stroke [doubled]) and CHA(2)DS(2)VASc-score (Congestive Heart failure, hypertension, Age ≥75 years [doubled], Diabetes, Stroke [doubled], Vascular disease, Age 65–74 years, Sex category [female sex]) was calculated in 150,408 consecutive patients, referred to the University Hospital of Rostock between 2007 and 2012. All factors constituting these scores and a history of AF were prospectively documented with the ICD-10 admission codes. RESULTS: Mean age of our study population was 67.6 ± 13.6 years with a mean CHADS(2)-score of 1.65 ± 0.92 and CHA(2)DS(2)VASc-score of 3.04 ± 1.42. AF was prevalent in 15.9% of the participants. The prevalence of AF increased significantly with every CHADS(2)- and CHA(2)DS(2)VASc-score point up to 54.2% in CHADS(2)-score of 6 and 71.4% in CHA(2)DS(2)VASc-score of 9 (P < 0.001). CONCLUSION: The prevalence of AF increases with increasing CHADS(2)- and CHA(2)DS(2)VASc-score. In intermediate scores intensified monitoring may be recommended. In high scores, thromboembolic complications occurred irrespective of the presence of AF and anticoagulant therapy may be initiated irrespective of documented AF.
format Online
Article
Text
id pubmed-4282384
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-42823842015-01-15 Prevalence of Atrial Fibrillation in Patients with High CHADS(2)- and CHA(2)DS(2)VAS(c)-Scores: Anticoagulate or Monitor High-Risk Patients? Tischer, Tina S Schneider, Ralph Lauschke, Jörg Nesselmann, Catharina Klemm, Anke Diedrich, Doreen Kundt, Günther Bänsch, Dietmar Pacing Clin Electrophysiol Electrophysiology BACKGROUND: In patients with known atrial fibrillation (AF) different scores are utilized to estimate the risk of thromboembolic events and guide oral anticoagulation. Diagnosis of AF strongly depends on the duration of electrocardiogram monitoring. The aim of this study was to use established scores to predict the prevalence of AF. METHODS: The CHADS(2)- (Congestive Heart failure, hypertension, Age >75 years, Diabetes, Stroke [doubled]) and CHA(2)DS(2)VASc-score (Congestive Heart failure, hypertension, Age ≥75 years [doubled], Diabetes, Stroke [doubled], Vascular disease, Age 65–74 years, Sex category [female sex]) was calculated in 150,408 consecutive patients, referred to the University Hospital of Rostock between 2007 and 2012. All factors constituting these scores and a history of AF were prospectively documented with the ICD-10 admission codes. RESULTS: Mean age of our study population was 67.6 ± 13.6 years with a mean CHADS(2)-score of 1.65 ± 0.92 and CHA(2)DS(2)VASc-score of 3.04 ± 1.42. AF was prevalent in 15.9% of the participants. The prevalence of AF increased significantly with every CHADS(2)- and CHA(2)DS(2)VASc-score point up to 54.2% in CHADS(2)-score of 6 and 71.4% in CHA(2)DS(2)VASc-score of 9 (P < 0.001). CONCLUSION: The prevalence of AF increases with increasing CHADS(2)- and CHA(2)DS(2)VASc-score. In intermediate scores intensified monitoring may be recommended. In high scores, thromboembolic complications occurred irrespective of the presence of AF and anticoagulant therapy may be initiated irrespective of documented AF. BlackWell Publishing Ltd 2014-12 2014-07-29 /pmc/articles/PMC4282384/ /pubmed/25621351 http://dx.doi.org/10.1111/pace.12470 Text en ©2014 The Authors. Pacing and Clinical Electrophysiology published by Wiley Periodicals, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Electrophysiology
Tischer, Tina S
Schneider, Ralph
Lauschke, Jörg
Nesselmann, Catharina
Klemm, Anke
Diedrich, Doreen
Kundt, Günther
Bänsch, Dietmar
Prevalence of Atrial Fibrillation in Patients with High CHADS(2)- and CHA(2)DS(2)VAS(c)-Scores: Anticoagulate or Monitor High-Risk Patients?
title Prevalence of Atrial Fibrillation in Patients with High CHADS(2)- and CHA(2)DS(2)VAS(c)-Scores: Anticoagulate or Monitor High-Risk Patients?
title_full Prevalence of Atrial Fibrillation in Patients with High CHADS(2)- and CHA(2)DS(2)VAS(c)-Scores: Anticoagulate or Monitor High-Risk Patients?
title_fullStr Prevalence of Atrial Fibrillation in Patients with High CHADS(2)- and CHA(2)DS(2)VAS(c)-Scores: Anticoagulate or Monitor High-Risk Patients?
title_full_unstemmed Prevalence of Atrial Fibrillation in Patients with High CHADS(2)- and CHA(2)DS(2)VAS(c)-Scores: Anticoagulate or Monitor High-Risk Patients?
title_short Prevalence of Atrial Fibrillation in Patients with High CHADS(2)- and CHA(2)DS(2)VAS(c)-Scores: Anticoagulate or Monitor High-Risk Patients?
title_sort prevalence of atrial fibrillation in patients with high chads(2)- and cha(2)ds(2)vas(c)-scores: anticoagulate or monitor high-risk patients?
topic Electrophysiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282384/
https://www.ncbi.nlm.nih.gov/pubmed/25621351
http://dx.doi.org/10.1111/pace.12470
work_keys_str_mv AT tischertinas prevalenceofatrialfibrillationinpatientswithhighchads2andcha2ds2vascscoresanticoagulateormonitorhighriskpatients
AT schneiderralph prevalenceofatrialfibrillationinpatientswithhighchads2andcha2ds2vascscoresanticoagulateormonitorhighriskpatients
AT lauschkejorg prevalenceofatrialfibrillationinpatientswithhighchads2andcha2ds2vascscoresanticoagulateormonitorhighriskpatients
AT nesselmanncatharina prevalenceofatrialfibrillationinpatientswithhighchads2andcha2ds2vascscoresanticoagulateormonitorhighriskpatients
AT klemmanke prevalenceofatrialfibrillationinpatientswithhighchads2andcha2ds2vascscoresanticoagulateormonitorhighriskpatients
AT diedrichdoreen prevalenceofatrialfibrillationinpatientswithhighchads2andcha2ds2vascscoresanticoagulateormonitorhighriskpatients
AT kundtgunther prevalenceofatrialfibrillationinpatientswithhighchads2andcha2ds2vascscoresanticoagulateormonitorhighriskpatients
AT banschdietmar prevalenceofatrialfibrillationinpatientswithhighchads2andcha2ds2vascscoresanticoagulateormonitorhighriskpatients